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Some of the pituitary adenomas are invasive and spread into neighboring tissues. In previous studies, the invasion of 
pituitary adenomas is thought to be associated with epithelial-mesenchymal transition (EMT). In addition to that, we 
thought that mesenchymal stem cells (MSCs) exist in relevant microenvironment in pituitary adenoma. However, it has 
been little known about the existence of MSCs from pituitary adenoma. So we investigated whether mesenchymal 
stem-like cells (MSLCs) can be isolated from the pituitary adenoma specimen. We isolated and cultured candidate 
MSLCs from the fresh pituitary adenoma specimen with the same protocols used in culturing bone marrow derived 
MSCs (BM-MSCs). The cultured candidate MSLCs were analyzed by fluorescence-activated cell sorting (FACS) for 
surface markers associated with MSCs. Candidate MSLCs were exposed to mesenchymal differentiation conditions to 
determine the mesenchymal differentiation potential of these cells. To evaluate the tumorigenesis of candidate MSLCs 
from pituitary adenoma, we implanted these cells into the brain of athymic nude mice. We isolated cells resembling 
BM-MSCs named pituitary adenoma stroma mesenchymal stem-like cells (PAS-MSLCs). PAS-MSLCs were spindle 
shaped and had adherent characteristics. FACS analysis identified that the PAS-MSLCs had a bit similar surface markers 
to BM-MSCs. Isolated cells expressed surface antigen, positive for CD105, CD75, and negative for CD45, NG2, and 
CD90. We found that these cells were capable of differentiation into adipocytes, osteocytes and chondrocytes. Tumor 
was not developed in the nude mice brains that were implanted with the PAS-MSLCs. In this study, we showed that 
MSLCs can be isolated from a pituitary adenoma specimen which is not tumorigenic. 
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INTRODUCTION 
 
Pituitary adenomas are common neoplasms in the sellar 
region that have wide range of biological behavior, in term 
of hormonal and proliferative activities (Asa and Ezzat, 
1998). Confined to the sella turcica, pituitary adenomas are 
slow growing and they are demarcated from the adjacent 
normal pituitary tissue (Kovacs et al., 2001). However, 
several pituitary adenomas are invasive, exhibit a more 
rapid pace of growth, and spread into neighboring tissues. 
In other words, pituitary adenomas may be invasive, while 
still having a histologically benign feature (Martins et al., 
1965; Scheithauer et al., 1986). 
Epithelial-Mesenchymal Transition (EMT) is a cellular 
program through which differentiated epithelial cells could 
be transformed into mesenchymal cells. EMT is a process 
that allows polarized epithelial cells to present a mesen- 
chymal cell phenotype whereby undergoes remodeling of 
the cytoskeleton and acquires migratory abilities and a 
mesenchymal-like gene expression program (Lekva et al., 
2012; Mirantes et al., 2013). Tumor invasion and metastasis 
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are associated with signals responsible for EMT (Yang and 
Weinberg, 2008). A few examples exist where epithelial 
and mesenchymal states in the same cell line display 
dramatically different cancer activities (Thompson et al., 
2005). The mesenchymal state possesses more motile and 
invasive characteristics in vitro and indicates more tumori- 
genic and often selectively metastatic state (Ackland et al., 
2003; Donald et al., 2005). It is possible to think that the 
invasiveness of pituitary adenoma might be related to EMT. 
Latest research identified that the invasive pituitary 
adenoma cells acquire different patterns: mesenchymal, and 
leucocyte/amoeboid patterns (del Pliego et al., 2013). In 
addition, several brain tumors have been studied about the 
presence of cells which are similar to mesenchymal stem 
cells (Kim et al., 2013; Kwak et al., 2013; Lim et al., 2013). 
Accordingly, we have taken profound interest in tumor 
microenvironment, especially mesenchymal stem-like cells 
(MSLCs) which are similar to bone marrow-mesenchymal 
stem cells (BM-MSCs) (Kim et al., 2011; Kim et al., 2013). 
However, it is unknown that mesenchymal stem cells 
exist in pituitary adenoma. The purpose of this study is to 
address whether mesenchymal stem like cells can be isolated 
from pituitary adenoma in patients associated with the 
invasiveness of the tumor. We isolated pituitary adenoma 
stroma mesenchymal stem like cells (PAS-MSLCs) and 
studied this based on cell morphology, differential potential, 
surface antigens, and non-oncogenic potential. 
 
MATERIALS AND METHODS 
Single cell isolation and PAS-MSLCs culture 
Specimen from a patient with human pituitary adenoma 
was freshly obtained from operating room. Approval was 
obtained from the Institutional Review Boards of our 
institutes (KC10SNSI0466). Informed consent was provided 
according to the Declaration of Helsinki. For isolation of 
PAS-MSLCs from pituitary adenoma specimen, we followed 
proven methods for MSC isolation from bone marrow 
(Lennon and Caplan, 2006; Mareschi et al., 2001), normal 
brain (Kang et al., 2010) and gliomas (Kim et al., 2013). 
We performed the isolation procedure within 60 minutes of 
pituitary adenoma removal using a mechanical dissociation 
method. Surgical specimens were minced and dissociated 
with a scalpel in minimal essential medium-α (MEMα; 
Mediatech, Herndon, VA, USA) and then passed through a 
series of cell strainers with 100-μm nylon mesh (BD Falcon, 
Franklin Lakes, NJ, USA). Cell suspensions were washed 
twice in MEMα, and single-cell suspensions were placed 
in a 10-cm2 cell culture dish at a density of 2 × 106 cell/ 
cm2. These cells were cultured in complete MSC medium 
consisting of MEMα, 10% fetal bovine serum (FBS; Lonza, 
Basel, Switzerland), 2 mM L-glutamine (Mediatech), and 
antibiotic-antimycotic solution (100x, Gibco, Invitrogen 
Korea, Seoul, Korea). After 24 hours, non-adherent cells 
were removed by washing with phosphate-buffered saline 
(PBS; Mediatech) twice, and the adherent cells were 
cultured until they reached confluence. The cells were then 
trypsinized (0.25% trypsin with 0.1% EDTA) and sub-
cultured at a density of 5,000 cells/cm2. The cells were 
cultured continuously through 3~4 passages, consistent 
with their role as progenitor/stem cells. Cell cultures were 
observed with an inverted phase-ontrast microscope (IX71 
Inverted Microscope; Olympus, Tokyo, Japan) to determine 
their morphology. Photographs of cells were obtained with a 
digital camera (DP70 Digital Microscope Camera; Olympus), 
using DP Controller software (Olympus) at each passage. 
Flow cytometry analysis 
To investigate the surface antigen expression profile, 
candidate PAS-MSLCs were counted, washed in PBS 
(Mediatech), and pellets were resuspended in fluorescent-
activated cell sorting (FACS) buffer (PBS with 10% FBS) 
at a concentration of 5 × 105 cells per 100 μl. This single-
cell suspensions was incubated at 4℃ for 30 minutes with 
phycoerythrin, fluorescein isothiocyanate (FITC), Alexa 
Fluor 647, or allophycocyanin-conjugated antibodies against 
CD105 at a concentration of 0.25 μg/100 μl FACS buffer 
(eBioscience, San Diego, CA, USA), CD45 at a concen- 
tration of 5 μg/100 μl FACS buffer (BD Pharmingen, San 
Diego, CA, USA), CD73 at a concentration of 5 μg/100 μl 
FACS buffer (BD Pharmingen), CD90 at a concentration 
of 0.25 μg/100 μl FACS buffer (eBioscience), CD31 at a 
concentration of 0.5 μg/100 μl FACS buffer (eBiosciece), 
and nerve/glial antigen 2 (NG2) at a concentration of 2.5 
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μg/100 μl FACS buffer (R&D Systems, Minneapolis, MN, 
USA). For the detection of NG2 proteoglycan, an FITC-
conjugated secondary antibody (Millipore, Billerica, MA, 
USA) was used following primary antibody incubation 
(NG2 antibody; Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA). FACS analysis was performed using a 
FACS vantage SE (BD Biosciences) flow cytometry system 
equipped with Flowjo software (Tree Star, Inc., Ashland, 
OR, USA), and 30,000 events were recorded for each 
sample. For isolation of MSLCs among heterogeneous cell 
population, we assumed positive for surface antigen analysis 
as more than 10% of cells in FACS and negative as less 
than 5% in FACS (Kim et al., 2013) because we merely try 
to show presence of MSLCs among heterogeneous cells, 
instead of identical MSCs isolation (Dominici et al., 2006). 
Mesenchymal differentiation 
To determine the mesenchymal differentiation potential 
of candidate PAS-MSLCs, we used a proven trilineage 
differentiation test identical to that described previously 
(Kim et al., 2013; Lennon and Caplan, 2006; Mareschi et 
al., 2001). Briefly, we tested the capacity of candidate PAS-
MSLCs to differentiate along adipogenic, osteogenic, and 
chondrogenic lineages. For adipogenic differentiation, PAS-
MSLCs were seeded in a six-well plate at a density of 4 × 
104 cells/cm2 in complete MSC medium. At confluence, cell 
differentiation was induced with adipogenic differentiation 
medium from the adipogenic differentiation BulletKit 
(Lonza Walkersville, Walkersville, MD, USA). This cell 
was fed with fresh medium every 3~4 days for 3 weeks. In 
control experiments, cells were incubated for the same 
period of time in complete MSC medium. On day 21, the 
cells were washed in PBS (Mediatech) and fixed in 10% 
formalin (Fisher Scientific, Fair Lawn, NJ, USA) for 1 hour 
at room temperature. After fixation, the cells were rinsed 
with deionized water several times, followed by the addition 
of 60% isopropanol (Pharmco-AAPER, Brook-field, CT, 
USA), and were allowed to sit for 5 min. Oil red O solution 
(Sigma) was then added to each well. After 5 minutes, the 
cells were rinsed with deionized water and briefly counter-
stained with hematoxylin (Sigma). 
For osteogenic differentiation, candidate PAS-MSLCs was 
plated at a density of 3 × 104 cells/cm2 in a six-well plate. 
The next day, the medium was replaced with osteogenic 
differentiation medium from the osteogenic differentiation 
BulletKit (Lonza Walkersville). These were fed with fresh 
medium every 3~4 days for 3 weeks. In control experiment, 
cells were incubated for the same period of time in complete 
MSC medium. On day 21, cell culture was washed twice 
with PBS (Mediatech) and fixed in 70% ice-cold ethanol 
(Pharmco-AAPER) for 1 hour, followed by washing with 
deionized water. The cells were stained with 40 mM Alizarin 
red (pH 4.2; Sigma) for 10 min at room temperature with 
rotation, followed by washing with deionized water five 
times. 
For chondrogenic differentiation, a modification in 
previous protocols was used. Candidate PAS-MSLCs was 
trypsinized and washed in serum-containing medium. 
Aliquots of 250,000 cells suspended in 0.5 ml of medium 
were placed in 15-ml conical polypropylene tubes (SPL, 
Pocheon, Gyeonggi, Korea). The cells were then gently 
centrifuged for 5 min at 150 × g and left at the bottom of 
the tubes, which were placed in an incubator with caps 
loosened to permit gas exchange. The cells formed small 
pellets that were cultured for 3 weeks in chondrogenic 
differentiation medium from the chondrogenic differen- 
tiation BulletKit (Lonza Walkersville) and 20 μg/ml of 
TGF-β3 (Ontogeny Research Products, Cambridge, MA, 
USA). Every 3~4 days, the cells were fed with fresh 
medium. In control experiments, the cells were incubated 
for the same period of time in complete MSC medium. 
These pellets were fixed in 10% formalin for 1 hour at room 
temperature and then embedded in paraffin sections, there 
after stained with toluidine blue (Sigma) for proteoglycans 
and glycosaminoglycans. 
Animal subjects 
4- to 8-week-old male athymic nude mice (Central Lab. 
Animal Inc., Seoul, Republic of Korea) were used to check 
tumorigenesis of PAS-MSLCs. Mice were housed in micro-
isolator cages under sterile conditions and observed for at 
least 1 week before study initiation to ensure proper health. 
Lighting, temperature, and humidity were controlled centrally. 
All experimental procedures were approved by our In- 
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stitutional Animal Care and Use Committee. Every day, we 
checked the body weight of the mice. If the body weight 
decreased more than 15% compared with the original body 
weight, mice were euthanized according to protocol. The 
brain was dissected and placed in formalin for pathological 
study. 
Xenografting of candidate PAS-MSLCs 
Mice were anesthetized with a solution of Zoletil® (30 
mg/kg; Virbac Korea, Seoul, Korea) and xylaxine (10 mg/ 
kg; Bayer Korea, Seoul, Korea) delivered intraperitoneally. 
Candidate PAS-MSLCs were implanted into the right frontal 
lobe of nude mice using a guide-screw system within the 
skull, as described previously (Lal et al., 2000). Mice 
received 5 × 105 candidate PAS-MSLCs via a Hamilton 
syringe (Dongwoo Science Co., Seoul, Korea) inserted to a 
depth of 4.5 mm. Each candidate MSLCs were injected into 
three mice simultaneously using a multiple micro infusion 
syringe pump (Harvard Apparatus, Holliston, MA, USA) at 
a speed of 0.5 μl/min as previously described (Kang et al., 
2010; Kim et al., 2011; Kim et al., 2013; Lal et al., 2000; 
Nakamizo et al., 2005). At least 180~200 days after 
injection, we carefully removed mice brains to see whether 
tumorigenesis occurred with H/E staining. 
 
RESULTS 
Patient information 
The tumor specimen was obtained from a 62-year-old 
female patient. Preoperative magnetic resonance image 
(MRI) revealed hypoenhancing intra- and supra sella mass 
(Fig. 1). The tumor was resected by transsphenoid approach. 
Pathologic diagnosis revealed pituitary adenoma. Immuno- 
histochemistry stain showed negative for ACTH, prolactin, 
GH, TSH, estrogen and positive for β-HCG. 
Isolation of candidate MSLCs from a pituitary adenoma 
To isolate PAS-MSLCs from a pituitary adenoma 
specimen, fresh pituitary adenoma specimen was obtained 
and then cultured. Adherent cells were cultured discarding 
non-adherent cells in MSCs media, and grew as spindle-
shaped cells (Fig. 2). 
Surface antigen expression of candidate MSLCs 
Adherent cells were analyzed by flow cytometry for 
mesenchymal (CD105, CD90, and CD73), leukocyte (CD- 
45), pericyte (NG2) surface marker that were associated 
Fig. 1. Magnetic resonance image (MRI) of a patient. Sagittal
MRI showed that there was about 1.6 × 1.2 × 1.3 cm sized
hypoenhancing intra and suprasella mass. The mass was abutting
to optic chiasm with mild compression. 
Fig. 2. Morphology of pituitary adenoma stroma mesen-
chymal stem-like cells (PAS-MSLCs) from specimen of pituitary
adenoma. Isolated cells grew as spindle-shaped cells in MSC 
culture conditions and were resembled bone marrow-derived MSCs
(BM-MSCs). Original magnification ×100. 
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with human MSCs. Although there is no pathognomonic 
marker for MSC, it is generally agreed that human MSCs 
are positive for CD105, CD90, and CD73, and negative 
for CD45. In this study, isolated candidate PAS-MSLCs 
expressed a bit similar surface antigen pattern for MSCs, 
positive for CD105 (31.4%), CD73 (49%), and negative for 
CD45 (0.4%), NG2 (1.3%) , and CD90 (1.9%) (Fig. 3). 
Mesenchymal differentiation of candidate PAS-MSLCs 
To identify whether PAS-MSLCs have the mesenchymal 
differentiation capacity, PAS-MSLCs were cultured in the 
mesenchymal trilineage-inducing media. During osteogenic 
induction of PAS-MSLCs, cells filled with calcium deposits 
were confirmed by Alizarin Red staining 3 weeks after the 
initiation of the induction (Fig. 4B). In the control experi- 
ments, we showed that cells did not have calcium deposits 
in non-inducing medium. After cells were cultured in 
adipogenic differentiation condition, lipid droplets formed 
in cells were detected by Oil Red O staining (Fig. 4E). In the 
control experiments, adipogenesis was not detected. Finally, 
PAS-MSLCs were cultured and pelleted in chondrogenic 
differentiation medium for 3 weeks. Then these cells were 
stained by toluidine blue for detection of proteoglycans 
and glycosaminoglycans in the pellet matrix (Fig. 4F). 
Chondrogenesis was not detected in control culture. 
No tumorgenicity of PAS-MSLCs 
PAS-MSLCs were tested for lack of tumorigenesis 
capacity in vivo. Nude mice intracranially implanted with 
pituitary adenoma cells were monitored for about 6 months 
and sacrificed upon weight loss of 15% and over as 
compared to the maximal weight. All mice that implanted 
with were PAS-MSLCs survived more than 6 month. 
According to pathologic result, we found no tumorigenesis 
from which we could conclude the absence of tumorigenesis 
characteristics in PAS-MSLCs (Fig. 5). 
 
DISCUSSION 
 
In this study, we showed that MSLCs were isolated in 
pituitary adenoma specimen. Immunohistochemistry for 
ACTH, prolactin, GH, TSH, estrogen were all negative 
Fig. 3. PAS-MSLCs analyzed by flow cytometry for MSCs surface antigens. We identified mesenchymal (CD105, CD90, and CD73),
leukocyte (CD45), and pericyte (NG2) surface antigen expression. PAS-MSLCs presented positive for CD105/CD73 and negative for 
CD90/CD45/NG2. 
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except β-HCG in this pituitary adenoma tissue. Cells from 
PA specimen were successfully isolated and cultured in 
common MSCs culture conditions, as described previously 
(Kim et al., 2013; Lennon and Caplan, 2006; Mareschi et 
al., 2001). These cells exhibited adherence to a plastic 
 
 
 
 
 
 
 
 
 
 
surface (Fig. 1). Isolated cells in pituitary adenoma were 
analyzed of the presence of the surface antigens CD105/ 
CD90/CD73/CD45, which are typical surface markers of 
MSLCs used in other studies (Kim et al., 2013; Kwak et al., 
2013; Lim et al., 2013). These cells exhibited positive for 
Fig. 4. PAS-MSLCs identified for trilineage mesenchymal differentiation capacity. (A) In non-induced medium, PAS-MSLCs were 
negative for osteogenesis. (B) Osteogenic differentiation of PAS-MSLCs was seen calcium deposition. (C) In control medium, PAS-MSLCs
were negative for adipogenesis. (D) Adipogenic differentiation of PAS-MSLCs was seen intracellular lipid droplets. (E) PAS-MSLCs were
negative for toluidine blue staining in non-induced medium. (F) Chondrogenic differentiation of PAS-MSLCs was stained proteoglycans 
and glycosaminoglycans by toluidine blue. 
Fig. 5. No tumorigenesis capacity of PAS-MSLCs. Nude mice brains implanted with PAS-MSLCs were sectioned and showed no
tumorigenesis. (A) Original magnification ×20 (H&E) (B) Original magnification ×200 (H&E). 
A C E 
B D F 
B A 
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CD105, CD73, and negative for CD45, NG2, and CD90 
surface antigen expression profile (Fig. 2). PAS-MSLCs 
had a similar surface antigen profile to MSLCs, except 
negative expression about CD90. In addition, these cells 
were capable of trilineage diffenentation to adipogenic, 
osteogenic and chodrogenic (Fig. 3), and lack of tumori- 
genesis (Fig. 4). Although the obtained cells do not com- 
pletely equated to MSCs, some features can be seen similar 
to the MSCs (Dominici et al., 2006; Chamberlain et al., 
2007). Accordingly, isolated cells in pituitary adenoma 
were called mesenchymal stem-like cells. 
This study have an obvious limitation due to the small 
number of PA specimens (n=1). However, our hypothesis 
that PAS-MSLCs could be isolated from specimen was 
substantiated. We did not identify EMT the specimens 
from the patients with pituitary adenoma. However, a few 
research present that pituitary adenoma are invasive (Kovacs 
et al., 2001; Martins et al., 1965; Scheithauer et al., 1986). 
Previously, it was known that the invasion was associated 
with EMT (Guarino et al., 2007). Because there is no 
single marker to define the MSCs, we adapted the 2006' 
International Society for Cellular Therapy (ISCT)'s minimal 
requirement to define the MSCs (Dominici et al., 2006). 
Recent studies have reported the presence of MSC or 
MSLCs in the stroma of brain and other tumor (El-Haibi 
and Karnoub, 2010; Kang et al., 2010; Karnoub et al., 
2007), but little information is known about MSLCs in 
pituitary adenoma (PA). PAS-MSLCs are a kind of stromal 
cells in tumor microenvironment and no tumorigenic cells 
unlike cancer stem cells (Kim et al., 2013; Kwak et al., 
2013; Lim et al., 2013), so no tumorigenic capability of 
PAS-MSLCs is one of most important characteristics which 
are property of tumor stromal cells although these cells 
were obtained from tumor. In case of invasive PA, we 
thought that the invasiveness of PA were from EMT that is 
the characteristic of mesenchyme (Lekva et al., 2012; 
Mirantes et al., 2013). In addition, because the EMT is the 
characteristic of mesenchyme, we thought that there is much 
chance of existence of MSLCs in invasive PA. We will 
continue to research for mesenchymal transition of pituitary 
adenomas and the consequential invasion mechanism from 
the relationship between mesenchymal molecular signature 
of pituitary adenomas and PAS-MSLCs, which was not 
directly addressed in the present study. Future studies should 
clarify the biological relationship between PAS-MSLCs 
and pituitary adenomas invasion, the experiments of which 
is about to be undertaken in our institute. 
Recently, the isolation (Kim et al., 2011; Kim et al., 
2013) and function (Kong et al., 2013) of MSCs/MSLCs 
from gliomas were reported. Pituitary tumor cells were 
acquired mesenchymal patterns in previous study (del Pliego 
et al., 2013). Our study has demonstrated the existence of 
MSLCs from specimen of pituitary adenoma. This study 
will lead to the development of therapeutic strategies for PA 
patients because it represents a small step in understanding 
the pituitary adenoma. 
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